Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers

Median duration of daratumumab (DARA) administration for treatment of multiple myeloma is 3-7 hours for the intravenous formulation (DARA IV) and 3-5 minutes for the subcutaneous formulation (DARA SC). Here, we describe clinical administration characteristics of DARA using a novel method for data ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Soefje, Scott A., Carpenter, Corinne, Carlson, Katherine, Awasthi, Samir, Lin, Thomas S., Kaila, Shuchita, Tarjan, Daniel, Kayal, Nikhil, Kirkup, Christian, Wagner, Tyler E., Gray, Kathleen S., Kumar, Shaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL CONTRIBUTIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101255/
https://www.ncbi.nlm.nih.gov/pubmed/36758192
http://dx.doi.org/10.1200/OP.22.00421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101255/
https://www.ncbi.nlm.nih.gov/pubmed/36758192
http://dx.doi.org/10.1200/OP.22.00421

Ejemplares similares